- The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
-
Huang YH, Hsu KH, Chin CS, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, Chen JJ, Chang GC
- KMID: 2528213
- Cancer Res Treat.
- 2022 Apr;54(2):434-444.
- doi: 10.4143/crt.2021.671
Purpose The aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients. Materials and Methods From... -
- CITED
-
- Close
- SHARE
-
- Close
- Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
-
Tseng JS, Yang TY, Chen KC, Hsu KH, Huang YH, Su KY, Yu SL, Chang GC
- KMID: 2424789
- Cancer Res Treat.
- 2018 Oct;50(4):1164-1174.
- doi: 10.4143/crt.2017.460
PURPOSE: Epidermal growth factor receptor (EGFR) T790M mutation serves as an important predictor of osimertinib efficacy. However, little is known about how it works among patients with various timings of... -
- CITED
-
- Close
- SHARE
-
- Close
- The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
-
Huang YH, Hsu KH, Tseng JS, Chen KC, Hsu CH, Su KY, Chen JJ, Chen HW, Yu SL, Yang TY, Chang GC
- KMID: 2424801
- Cancer Res Treat.
- 2018 Oct;50(4):1294-1303.
- doi: 10.4143/crt.2017.512
PURPOSE: The main objective of this study was to investigate the relationship among the clinical characteristics and the frequency of T790M mutation in advanced epidermal growth factor receptor (EGFR)–mutant lung... -
- CITED
-
- Close
- SHARE
-
- Close
